Loading...
Header Logo
Keywords
Last Name
Institution

ZAHID H SIDDIK

Address1881 East Road
Houston TX 77054-3005
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Rodriguez-Aguayo C, Bayraktar E, Ivan C, Aslan B, Mai J, He G, Mangala LS, Jiang D, Nagaraja AS, Ozpolat B, Chavez-Reyes A, Ferrari M, Mitra R, Siddik ZH, Shen H, Yang X, Sood AK, Lopez-Berestein G. PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis. EBioMedicine. 2019 Feb; 40:290-304. PMID: 30655206.
      View in: PubMed
    2. Farooqi AA, de la Roche M, Djamgoz MBA, Siddik ZH. Overview of the oncogenic signaling pathways in colorectal cancer: Mechanistic insights. Semin Cancer Biol. 2019 Jan 08. PMID: 30633978.
      View in: PubMed
    3. Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, Langley RR, Jennings NB, Ivan C, Coffin JE, Armaiz GN, Bottsford-Miller J, Kim SB, Halleck MS, Hendrix MJ, Bornman W, Bar-Eli M, Lee JS, Siddik ZH, Lopez-Berestein G, Sood AK. ATP11B mediates platinum resistance in ovarian cancer. J Clin Invest. 2018 07 02; 128(7):3199. PMID: 29809169.
      View in: PubMed
    4. Prasad S, Tyagi AK, Siddik ZH, Aggarwal BB. Curcumin-Free Turmeric Exhibits Activity against Human HCT-116 Colon Tumor Xenograft: Comparison with Curcumin and Whole Turmeric. Front Pharmacol. 2017; 8:871. PMID: 29311914.
      View in: PubMed
    5. Bhatt M, Ivan C, Xie X, Siddik ZH. Drug-dependent functionalization of wild-type and mutant p53 in cisplatin-resistant human ovarian tumor cells. Oncotarget. 2017 Feb 14; 8(7):10905-10918. PMID: 28038466.
      View in: PubMed
    6. Altaf M, Monim-Ul-Mehboob M, Kawde AN, Corona G, Larcher R, Ogasawara M, Casagrande N, Celegato M, Borghese C, Siddik ZH, Aldinucci D, Isab AA. New bipyridine gold(III) dithiocarbamate-containing complexes exerted a potent anticancer activity against cisplatin-resistant cancer cells independent of p53 status. Oncotarget. 2017 Jan 03; 8(1):490-505. PMID: 27888799.
      View in: PubMed
    7. Xie X, He G, Siddik ZH. Functional Activation of Mutant p53 by Platinum Analogues in Cisplatin-Resistant Cells Is Dependent on Phosphorylation. Mol Cancer Res. 2017 03; 15(3):328-339. PMID: 28031409.
      View in: PubMed
    8. Thiabaud G, McCall R, He G, Arambula JF, Siddik ZH, Sessler JL. Activation of Platinum(IV) Prodrugs By Motexafin Gadolinium as a Redox Mediator. Angew Chem Int Ed Engl. 2016 10 04; 55(41):12626-31. PMID: 27377046.
      View in: PubMed
    9. Xie X, Lozano G, Siddik ZH. Heterozygous p53(V172F) mutation in cisplatin-resistant human tumor cells promotes MDM4 recruitment and decreases stability and transactivity of p53. Oncogene. 2016 09 08; 35(36):4798-806. PMID: 26876197.
      View in: PubMed
    10. Farooqi AA, Siddik ZH. Platelet-derived growth factor (PDGF) signalling in cancer: rapidly emerging signalling landscape. Cell Biochem Funct. 2015 Jul; 33(5):257-65. PMID: 26153649.
      View in: PubMed
    11. Tsimberidou AM, Said R, Culotta K, Wistuba I, Jelinek J, Fu S, Falchook G, Naing A, Piha-Paul S, Zinner R, Siddik ZH, He G, Hess K, Stewart DJ, Kurzrock R, Issa JP. Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy. Clin Epigenetics. 2015; 7:29. PMID: 25806091.
      View in: PubMed
    12. Thiabaud G, Arambula JF, Siddik ZH, Sessler JL. Photoinduced reduction of Pt(IV) within an anti-proliferative Pt(IV)-texaphyrin conjugate. Chemistry. 2014 Jul 14; 20(29):8942-7. PMID: 24961491.
      View in: PubMed
    13. Kim ES, Tang X, Peterson DR, Kilari D, Chow CW, Fujimoto J, Kalhor N, Swisher SG, Stewart DJ, Wistuba II, Siddik ZH. Copper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancer. Lung Cancer. 2014 Jul; 85(1):88-93. PMID: 24792335.
      View in: PubMed
    14. He G, Kuang J, Koomen J, Kobayashi R, Khokhar AR, Siddik ZH. Recruitment of trimeric proliferating cell nuclear antigen by G1-phase cyclin-dependent kinases following DNA damage with platinum-based antitumour agents. Br J Cancer. 2013 Oct 29; 109(9):2378-88. PMID: 24104967.
      View in: PubMed
    15. Moreno-Smith M, Lee SJ, Lu C, Nagaraja AS, He G, Rupaimoole R, Han HD, Jennings NB, Roh JW, Nishimura M, Kang Y, Allen JK, Armaiz GN, Matsuo K, Shahzad MM, Bottsford-Miller J, Langley RR, Cole SW, Lutgendorf SK, Siddik ZH, Sood AK. Biologic effects of dopamine on tumor vasculature in ovarian carcinoma. Neoplasia. 2013 May; 15(5):502-10. PMID: 23633922.
      View in: PubMed
    16. Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, Langley RR, Jennings NB, Ivan C, Coffin JE, Armaiz GN, Bottsford-Miller J, Kim SB, Halleck MS, Hendrix MJ, Bornman W, Bar-Eli M, Lee JS, Siddik ZH, Lopez-Berestein G, Sood AK. ATP11B mediates platinum resistance in ovarian cancer. J Clin Invest. 2013 May; 123(5):2119-30. PMID: 23585472.
      View in: PubMed
    17. Preihs C, Arambula JF, Magda D, Jeong H, Yoo D, Cheon J, Siddik ZH, Sessler JL. Recent developments in texaphyrin chemistry and drug discovery. Inorg Chem. 2013 Nov 04; 52(21):12184-92. PMID: 23557113.
      View in: PubMed
    18. Kim ES, Lee JJ, He G, Chow CW, Fujimoto J, Kalhor N, Swisher SG, Wistuba II, Stewart DJ, Siddik ZH. Tissue platinum concentration and tumor response in non-small-cell lung cancer. J Clin Oncol. 2012 Sep 20; 30(27):3345-52. PMID: 22891266.
      View in: PubMed
    19. Arambula JF, Sessler JL, Siddik ZH. A texaphyrin-oxaliplatin conjugate that overcomes both pharmacologic and molecular mechanisms of cisplatin resistance in cancer cells. Medchemcomm. 2012; 3(10):1275-1281. PMID: 23936624.
      View in: PubMed
    20. Martinez-Rivera M, Siddik ZH. Resistance and gain-of-resistance phenotypes in cancers harboring wild-type p53. Biochem Pharmacol. 2012 Apr 15; 83(8):1049-62. PMID: 22227014.
      View in: PubMed
    21. Le XF, Mao W, He G, Claret FX, Xia W, Ahmed AA, Hung MC, Siddik ZH, Bast RC. The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells. J Natl Cancer Inst. 2011 Sep 21; 103(18):1403-22. PMID: 21813412.
      View in: PubMed
    22. He G, Kuang J, Khokhar AR, Siddik ZH. The impact of S- and G2-checkpoint response on the fidelity of G1-arrest by cisplatin and its comparison to a non-cross-resistant platinum(IV) analog. Gynecol Oncol. 2011 Aug; 122(2):402-9. PMID: 21592546.
      View in: PubMed
    23. Arambula JF, Sessler JL, Siddik ZH. Overcoming biochemical pharmacologic mechanisms of platinum resistance with a texaphyrin-platinum conjugate. Bioorg Med Chem Lett. 2011 Mar 15; 21(6):1701-5. PMID: 21345675.
      View in: PubMed
    24. Preihs C, Arambula JF, Lynch VM, Siddik ZH, Sessler JL. Bismuth- and lead-texaphyrin complexes: towards potential a-core emitters for radiotherapy. Chem Commun (Camb). 2010 Nov 14; 46(42):7900-2. PMID: 20922235.
      View in: PubMed
    25. Rowe RW, Strebel FR, Proett JM, Deng W, Chan D, He G, Siddik Z, Bull JM. Fever-range whole body thermotherapy combined with oxaliplatin: a curative regimen in a pre-clinical breast cancer model. Int J Hyperthermia. 2010; 26(6):565-76. PMID: 20707651.
      View in: PubMed
    26. Arambula JF, Sessler JL, Fountain ME, Wei WH, Magda D, Siddik ZH. Gadolinium texaphyrin (Gd-Tex)-malonato-platinum conjugates: synthesis and comparison with carboplatin in normal and Pt-resistant cell lines. Dalton Trans. 2009 Dec 28; (48):10834-40. PMID: 20023913.
      View in: PubMed
    27. Kurokawa T, He G, Siddik ZH. Protein kinase inhibitors emodin and dichloro-ribofuranosylbenzimidazole modulate the cellular accumulation and cytotoxicity of cisplatin in a schedule-dependent manner. Cancer Chemother Pharmacol. 2010 Feb; 65(3):427-36. PMID: 19529937.
      View in: PubMed
    28. Mangala LS, Zuzel V, Schmandt R, Leshane ES, Halder JB, Armaiz-Pena GN, Spannuth WA, Tanaka T, Shahzad MM, Lin YG, Nick AM, Danes CG, Lee JW, Jennings NB, Vivas-Mejia PE, Wolf JK, Coleman RL, Siddik ZH, Lopez-Berestein G, Lutsenko S, Sood AK. Therapeutic Targeting of ATP7B in Ovarian Carcinoma. Clin Cancer Res. 2009 Jun 01; 15(11):3770-80. PMID: 19470734.
      View in: PubMed
    29. Chen HH, Song IS, Hossain A, Choi MK, Yamane Y, Liang ZD, Lu J, Wu LY, Siddik ZH, Klomp LW, Savaraj N, Kuo MT. Elevated glutathione levels confer cellular sensitization to cisplatin toxicity by up-regulation of copper transporter hCtr1. Mol Pharmacol. 2008 Sep; 74(3):697-704. PMID: 18523133.
      View in: PubMed
    30. Lu Y, Li X, Liang K, Luwor R, Siddik ZH, Mills GB, Mendelsohn J, Fan Z. Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab. Cancer Res. 2007 Sep 01; 67(17):8240-7. PMID: 17804738.
      View in: PubMed
    31. He G, Kuang J, Huang Z, Koomen J, Kobayashi R, Khokhar AR, Siddik ZH. Upregulation of p27 and its inhibition of CDK2/cyclin E activity following DNA damage by a novel platinum agent are dependent on the expression of p21. Br J Cancer. 2006 Dec 04; 95(11):1514-24. PMID: 17088910.
      View in: PubMed
    32. He G, Siddik ZH, Huang Z, Wang R, Koomen J, Kobayashi R, Khokhar AR, Kuang J. Induction of p21 by p53 following DNA damage inhibits both Cdk4 and Cdk2 activities. Oncogene. 2005 Apr 21; 24(18):2929-43. PMID: 15735718.
      View in: PubMed
    33. Ali MS, Khan SR, Ojima H, Guzman IY, Whitmire KH, Siddik ZH, Khokhar AR. Model platinum nucleobase and nucleoside complexes and antitumor activity: X-ray crystal structure of [PtIV(trans-1R,2R-diaminocyclohexane)trans-(acetate)2(9-ethylguanine)Cl]NO3.H2O. J Inorg Biochem. 2005 Mar; 99(3):795-804. PMID: 15708801.
      View in: PubMed
    34. Mujoo K, Watanabe M, Khokhar AR, Siddik ZH. Increased sensitivity of a metastatic model of prostate cancer to a novel tetravalent platinum analog. Prostate. 2005 Jan 01; 62(1):91-100. PMID: 15389812.
      View in: PubMed
    35. Song IS, Savaraj N, Siddik ZH, Liu P, Wei Y, Wu CJ, Kuo MT. Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells. Mol Cancer Ther. 2004 Dec; 3(12):1543-9. PMID: 15634647.
      View in: PubMed
    36. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003 Oct 20; 22(47):7265-79. PMID: 14576837.
      View in: PubMed
    37. Mujoo K, Watanabe M, Nakamura J, Khokhar AR, Siddik ZH. Status of p53 phosphorylation and function in sensitive and resistant human cancer models exposed to platinum-based DNA damaging agents. J Cancer Res Clin Oncol. 2003 Dec; 129(12):709-18. PMID: 14513366.
      View in: PubMed
    38. Verschraegen CF, Kumagai S, Davidson R, Feig B, Mansfield P, Lee SJ, Maclean DS, Hu W, Khokhar AR, Siddik ZH. Phase I clinical and pharmacological study of intraperitoneal cis-bis-neodecanoato( trans- R, R-1, 2-diaminocyclohexane)-platinum II entrapped in multilamellar liposome vesicles. J Cancer Res Clin Oncol. 2003 Oct; 129(10):549-55. PMID: 14513369.
      View in: PubMed
    39. Mansouri A, Ridgway LD, Korapati AL, Zhang Q, Tian L, Wang Y, Siddik ZH, Mills GB, Claret FX. Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. J Biol Chem. 2003 May 23; 278(21):19245-56. PMID: 12637505.
      View in: PubMed
    40. Mukhopadhyay U, Thurston J, Whitmire KH, Siddik ZH, Khokhar AR. Preparation, characterization, and antitumor activity of new cisplatin analogues with 1-methyl-4-(methylamino)piperidine: crystal structure of [PtII(1-methyl-4-(methylamino) piperidine)(oxalate)]. J Inorg Biochem. 2003 Feb 01; 94(1-2):179-85. PMID: 12620689.
      View in: PubMed
    41. Siddik ZH. Biochemical and molecular mechanisms of cisplatin resistance. Cancer Treat Res. 2002; 112:263-84. PMID: 12481720.
      View in: PubMed
    42. Kuang J, He G, Huang Z, Khokhar AR, Siddik ZH. Bimodal effects of 1R,2R-diaminocyclohexane(trans-diacetato)(dichloro)platinum(IV) on cell cycle checkpoints. Clin Cancer Res. 2001 Nov; 7(11):3629-39. PMID: 11705886.
      View in: PubMed
    43. Ali Khan SR, Huang S, Shamsuddin S, Inutsuka S, Whitmire KH, Siddik ZH, Khokhar AR. Synthesis, characterization and cytotoxicity of new platinum(IV) axial carboxylate complexes: crystal structure of potential antitumor agent [PtIV(trans-1R,2R-diaminocyclohexane)trans(acetate)2Cl2]. Bioorg Med Chem. 2000 Mar; 8(3):515-21. PMID: 10732967.
      View in: PubMed
    44. Donato NJ, Perez M, Kang H, Siddik ZH, Ling YH, Perez-Soler R. EGF receptor and p21WAF1 expression are reciprocally altered as ME-180 cervical carcinoma cells progress from high to low cisplatin sensitivity. Clin Cancer Res. 2000 Jan; 6(1):193-202. PMID: 10656450.
      View in: PubMed
    45. Furui T, LaPushin R, Mao M, Khan H, Watt SR, Watt MA, Lu Y, Fang X, Tsutsui S, Siddik ZH, Bast RC, Mills GB. Overexpression of edg-2/vzg-1 induces apoptosis and anoikis in ovarian cancer cells in a lysophosphatidic acid-independent manner. Clin Cancer Res. 1999 Dec; 5(12):4308-18. PMID: 10632375.
      View in: PubMed
    46. Ali MS, Whitmire KH, Toyomasu T, Siddik ZH, Khokhar AR. Preparation, characterization, and antitumor activity of new cisplatin analogs with homopiperazines: crystal structure of [PtII(1-methylhomopiperazine)(methylmalonato)].2H2O. J Inorg Biochem. 1999 Nov-Dec; 77(3-4):231-8. PMID: 10643661.
      View in: PubMed
    47. Siddik ZH, Hagopian GS, Thai G, Tomisaki S, Toyomasu T, Khokhar AR. Role of p53 in the ability of 1,2-diaminocyclohexane-diacetato-dichloro-Pt(IV) to circumvent cisplatin resistance. J Inorg Biochem. 1999 Oct; 77(1-2):65-70. PMID: 10626356.
      View in: PubMed
    48. Hagopian GS, Mills GB, Khokhar AR, Bast RC, Siddik ZH. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV). Clin Cancer Res. 1999 Mar; 5(3):655-63. PMID: 10100719.
      View in: PubMed
    49. Yoshida M, Khokhar AR, Siddik ZH. Cytotoxicity and tolerance to DNA adducts of alicyclic mixed amine platinum(II) homologs in tumor models sensitive and resistant to cisplatin or tetraplatin. Oncol Rep. 1998 Sep-Oct; 5(5):1281-7. PMID: 9683851.
      View in: PubMed
    50. Shamsuddin S, Santillan CC, Stark JL, Whitmire KH, Siddik ZH, Khokhar AR. Synthesis, characterization, and antitumor activity of new platinum(IV) trans-carboxylate complexes: crystal structure of [Pt(cis-1,4-DACH)trans-(acetate)2Cl2]. J Inorg Biochem. 1998 Aug; 71(1-2):29-35. PMID: 9755489.
      View in: PubMed
    51. Siddik ZH, Mims B, Lozano G, Thai G. Independent pathways of p53 induction by cisplatin and X-rays in a cisplatin-resistant ovarian tumor cell line. Cancer Res. 1998 Feb 15; 58(4):698-703. PMID: 9485023.
      View in: PubMed
    52. Pusztai L, Siddik ZH, Mills GB, Bast RC. Physiologic and pathologic drug resistance in ovarian carcinoma--a hypothesis based on a clonal progression model. Acta Oncol. 1998; 37(7-8):629-40. PMID: 10050979.
      View in: PubMed
    53. Kudelka AP, Siddik ZH, Tresukosol D, Edwards CL, Freedman RS, Madden TL, Rastogi R, Hord M, Kim EE, Tornos C, Mante R, Kavanagh JJ. A phase II and pharmacokinetic study of enloplatin in patients with platinum refractory advanced ovarian carcinoma. Anticancer Drugs. 1997 Aug; 8(7):649-56. PMID: 9311439.
      View in: PubMed
    54. Perez-Soler R, Shin DM, Siddik ZH, Murphy WK, Huber M, Lee SJ, Khokhar AR, Hong WK. Phase I clinical and pharmacological study of liposome-entrapped NDDP administered intrapleurally in patients with malignant pleural effusions. Clin Cancer Res. 1997 Mar; 3(3):373-9. PMID: 9815694.
      View in: PubMed
    55. Khokhar AR, al-Baker S, Shamsuddin S, Siddik ZH. Chemical and biological studies on a series of novel (trans-(1R,2R)-, trans-(1S,2S)-, and cis-1,2-diaminocyclohexane)platinum(IV) carboxylate complexes. J Med Chem. 1997 Jan 03; 40(1):112-6. PMID: 9016335.
      View in: PubMed
    56. Kantarjian HM, Beran M, O'Brien S, Robertson L, Siddik Z, Yoshida M, Yang LY, Rios MB, Keating MJ, Meyer M, et al. Evaluation of CI-973, a platinum analogue, in refractory or relapsed acute leukemia. Leukemia. 1996 Mar; 10(3):396-401. PMID: 8642853.
      View in: PubMed
    57. Shamsuddin S, Takahashi I, Siddik ZH, Khokhar AR. Synthesis, characterization, and antitumor activity of a series of novel cisplatin analogs with cis-1,4-diaminocyclohexane as nonleaving amine group. J Inorg Biochem. 1996 Mar; 61(4):291-301. PMID: 8867456.
      View in: PubMed
    58. Klostergaard J, Leroux ME, Hsu HA, Hsi BP, Siddik ZH, Danhauser LL, Tomasovi SP. Multi-chemothermoimmunotherapy for human colon adenocarcinoma in vitro. Cancer Chemother Pharmacol. 1996; 37(3):235-41. PMID: 8529283.
      View in: PubMed
    59. Kudelka AP, Siddik ZM, Balat O, Kavanagh JJ. Carboplatin dosimetry in renal failure. J Clin Oncol. 1995 Aug; 13(8):2147-8. PMID: 7636563.
      View in: PubMed
    60. Davidson BS, Izzo F, Cromeens DM, Stephens LC, Siddik ZH, Curley SA. Collagen matrix cisplatin prevents local tumor growth after margin-positive resection. J Surg Res. 1995 Jun; 58(6):618-24. PMID: 7791337.
      View in: PubMed
    61. Wondergem J, Strebel FR, Stephens LC, Siddik ZH, Bull JM. Chronic effect of whole-body hyperthermia combined simultaneously with cis-diamminedichloroplatinum (II) on normal tissue in rat. Int J Hyperthermia. 1995 Jan-Feb; 11(1):37-47. PMID: 7714369.
      View in: PubMed
    62. Siddik ZH, Thai G, Yoshida M, Zhang YP, Khokhar AR. Tetravalent platinum complexes with ammine/amine carrier ligand configuration: circumvention of platinum resistance in vivo. Anticancer Drug Des. 1994 Dec; 9(6):495-509. PMID: 7880375.
      View in: PubMed
    63. Yoshida M, Khokhar AR, Siddik ZH. Circumvention of platinum resistance: structure-activity relationship for homologous series of ammine/amine platinum(II) complexes in L1210 cell lines. Anticancer Drug Des. 1994 Oct; 9(5):425-34. PMID: 7945726.
      View in: PubMed
    64. Yoshida M, Khokhar AR, Siddik ZH. Axial ligands and alicyclic ring size modulate the activity and biochemical pharmacology of ammine/cycloalkylamine-platinum(IV) complexes in tumor cells resistant to cis-diamminedichloroplatinum(II) or trans-1R,2R-1S,2S-diaminocyclohexanetetrachloroplatinum(IV). Cancer Res. 1994 Sep 01; 54(17):4691-7. PMID: 8062266.
      View in: PubMed
    65. Yoshida M, Khokhar AR, Kido Y, Ali-Osman F, Siddik ZH. Correlation of total and interstrand DNA adducts in tumor and kidney with antitumor efficacies and differential nephrotoxicities of cis-ammine/cyclohexylamine-dichloroplatinum(II) and cisplatin. Biochem Pharmacol. 1994 Aug 17; 48(4):793-9. PMID: 8080453.
      View in: PubMed
    66. Yoshida M, Khokhar AR, Siddik ZH. Biochemical pharmacology of homologous alicyclic mixed amine platinum(II) complexes in sensitive and resistant tumor cell lines. Cancer Res. 1994 Jul 01; 54(13):3468-73. PMID: 8012968.
      View in: PubMed
    67. Kido Y, Khokhar AR, Siddik ZH. Glutathione-mediated modulation of tetraplatin activity against sensitive and resistant tumor cells. Biochem Pharmacol. 1994 Apr 29; 47(9):1635-42. PMID: 8185678.
      View in: PubMed
    68. Siddik ZH, al-Baker S, Thai G, Khokhar AR. Modulatory effect of axial and equatorial ligands on antitumor activities of trans-1R,2R-diaminocyclohexane platinum(IV) complexes. Anticancer Drug Des. 1994 Apr; 9(2):139-51. PMID: 8166929.
      View in: PubMed
    69. Khokhar AR, al-Baker S, Siddik ZH. Synthesis and antitumor activity of 1,2-diaminocyclohexane platinum(IV) complexes. J Inorg Biochem. 1994 Apr; 54(1):39-47. PMID: 8151310.
      View in: PubMed
    70. Kido Y, Khokhar AR, Yoshida M, Thai GW, Siddik ZH. Pharmacokinetics of tetraplatin administered intraperitoneally with reduced glutathione in mice. Drug Metab Dispos. 1994 Mar-Apr; 22(2):312-7. PMID: 8013287.
      View in: PubMed
    71. Khokhar AR, Xu Q, Siddik ZH. Synthesis, characterization, and antitumor activity of amine platinum(II) and (IV) tellurate complexes. J Inorg Biochem. 1994 Mar; 53(4):295-301. PMID: 8169608.
      View in: PubMed
    72. Yoshida M, Khokhar AR, Zhang YP, Thai G, Siddik ZH. Kinetics of tissue disposition of cis-ammine/cyclohexylamine-dichloroplatinum(II) and cisplatin in mice bearing FSaIIC tumors. Cancer Chemother Pharmacol. 1994; 35(1):38-44. PMID: 7987975.
      View in: PubMed
    73. Siddik ZH, al-Baker S, Thai G, Khokhar AR. Antitumor activity of isomeric 1,2-diaminocyclohexane platinum(IV) complexes. J Cancer Res Clin Oncol. 1994; 120(7):409-14. PMID: 8188734.
      View in: PubMed
    74. Ohno S, Siddik ZH, Kido Y, Zwelling LA, Bull JM. Thermal enhancement of drug uptake and DNA adducts as a possible mechanism for the effect of sequencing hyperthermia on cisplatin-induced cytotoxicity in L1210 cells. Cancer Chemother Pharmacol. 1994; 34(4):302-6. PMID: 8033297.
      View in: PubMed
    75. Siddik ZH, Thai G, Yoshida M, Zhang YP, Khokhar AR. Ammine/amine platinum (II) complexes effective in vivo against murine tumors sensitive or resistant to cisplatin and tetraplatin. J Cancer Res Clin Oncol. 1994; 120(10):571-7. PMID: 7929527.
      View in: PubMed
    76. Kido Y, Khokhar AR, al-Baker S, Siddik ZH. Modulation of cytotoxicity and cellular pharmacology of 1,2-diaminocyclohexane platinum (IV) complexes mediated by axial and equatorial ligands. Cancer Res. 1993 Oct 01; 53(19):4567-72. PMID: 8402629.
      View in: PubMed
    77. Ohno S, Strebel FR, Stephens LC, Siddik ZH, Baba H, Makino M, Khokhar AR, Bull JM. Haematological toxicity of carboplatin and cisplatin combined with whole body hyperthermia in rats. Br J Cancer. 1993 Sep; 68(3):469-74. PMID: 8353037.
      View in: PubMed
    78. Khokhar AR, Deng Y, al-Baker S, Yoshida M, Siddik ZH. Synthesis and antitumor activity of ammine/amine platinum(II) and (IV) complexes. J Inorg Biochem. 1993 Aug 15; 51(3):677-87. PMID: 8409984.
      View in: PubMed
    79. Khokhar AR, Deng Y, Kido Y, Siddik ZH. Preparation, characterization, and antitumor activity of new ethylenediamine platinum(IV) complexes containing mixed carboxylate ligands. J Inorg Biochem. 1993 May 01; 50(2):79-87. PMID: 8487040.
      View in: PubMed
    80. Kido Y, Khokhar AR, Siddik ZH. Differential cytotoxicity, uptake and DNA binding of tetraplatin and analogous isomers in sensitive and resistant cancer cell lines. Anticancer Drugs. 1993 Apr; 4(2):251-8. PMID: 8490203.
      View in: PubMed
    81. Yang LY, Trujillo JM, Siciliano MJ, Kido Y, Siddik ZH, Su YZ. Distinct P-glycoprotein expression in two subclones simultaneously selected from a human colon carcinoma cell line by cis-diamminedichloroplatinum (II). Int J Cancer. 1993 Feb 01; 53(3):478-85. PMID: 8094074.
      View in: PubMed
    82. Siddik ZH, al-Baker S, Burditt TL, Khokhar AR. Differential antitumor activity and toxicity of isomeric 1,2-diaminocyclohexane platinum (II) complexes. J Cancer Res Clin Oncol. 1993; 120(1-2):12-6. PMID: 8270602.
      View in: PubMed
    83. Curley SA, Stone DL, Fuhrman GM, Hohn DC, Siddik ZH, Newman RA. Increased doxorubicin levels in hepatic tumors with reduced systemic drug exposure achieved with complete hepatic venous isolation and extracorporeal chemofiltration. Cancer Chemother Pharmacol. 1993; 33(3):251-7. PMID: 8269607.
      View in: PubMed
    84. Wondergem J, Siddik ZH, Strebel FR, Bull JM. Effect of whole body hyperthermia on cis-diamminedichloroplatinum (II)-induced antitumour activity and tissue Pt-distribution: do anaesthetics influence the therapeutic ratio? Eur J Cancer. 1993; 29A(4):549-54. PMID: 8435209.
      View in: PubMed
    85. Klostergaard J, Leroux E, Siddik ZH, Khodadadian M, Tomasovic SP. Enhanced sensitivity of human colon tumor cell lines in vitro in response to thermochemoimmunotherapy. Cancer Res. 1992 Oct 01; 52(19):5271-7. PMID: 1394131.
      View in: PubMed
    86. Kido Y, Khokhar AR, Siddik ZH. Pharmacokinetics of intravenously injected [3H]tetrachloro(D,L-trans)1,2-diaminocyclohexane platinum (IV) (tetraplatin) in mice. Drug Metab Dispos. 1992 Sep-Oct; 20(5):673-8. PMID: 1358571.
      View in: PubMed
    87. Ohno S, Strebel FR, Stephens LC, Siddik ZH, Makino M, Klostergaard J, Tomasovic SP, Khokhar AR, Bull JM. Increased therapeutic efficacy induced by tumor necrosis factor alpha combined with platinum complexes and whole-body hyperthermia in rats. Cancer Res. 1992 Aug 01; 52(15):4096-101. PMID: 1638521.
      View in: PubMed
    88. Khokhar AR, Xu Q, Newman RA, Kido Y, Siddik ZH. Synthesis, characterization, and antitumor activity of new chloroethylamine platinum complexes. J Inorg Biochem. 1992 Feb 15; 45(3):211-9. PMID: 1634893.
      View in: PubMed
    89. Vadiei K, Siddik ZH, Khokhar AR, al-Baker S, Sampedro F, Perez-Soler R. Pharmacokinetics of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II) and cisplatin given i.v. and i.p. in the rat. Cancer Chemother Pharmacol. 1992; 30(5):365-9. PMID: 1505075.
      View in: PubMed
    90. Wondergem J, Stephens LC, Strebel FR, Baba H, Ohno S, Siddik ZH, Newman RA, Bull JM. Effect of adriamycin combined with whole body hyperthermia on tumor and normal tissues. Cancer Res. 1991 Jul 01; 51(13):3559-67. PMID: 2054792.
      View in: PubMed
    91. Khokhar AR, Xu QY, Newman RA, Siddik ZH. Preparation, characterization, and antitumor activity of water-soluble aminoalkanol platinum(II) complexes. J Inorg Biochem. 1991 Jul; 43(1):57-63. PMID: 1940901.
      View in: PubMed
    92. Baba H, Stephens LC, Strebel FR, Siddik ZH, Newman RA, Ohno S, Bull JM. Protective effect of ICRF-187 against normal tissue injury induced by adriamycin in combination with whole body hyperthermia. Cancer Res. 1991 Jul 01; 51(13):3568-77. PMID: 1905199.
      View in: PubMed
    93. Ohno S, Siddik ZH, Baba H, Stephens LC, Strebel FR, Wondergem J, Khokhar AR, Bull JM. Effect of carboplatin combined with whole body hyperthermia on normal tissue and tumor in rats. Cancer Res. 1991 Jun 01; 51(11):2994-3000. PMID: 2032236.
      View in: PubMed
    94. Garteiz D, Siddik ZH, Newman RA. In vitro and in vivo murine metabolism of spirogermanium. Drug Metab Dispos. 1991 Jan-Feb; 19(1):44-7. PMID: 1673420.
      View in: PubMed
    95. Khokhar AR, Xu QY, Siddik ZH. Synthesis, characterization, and antitumor activity of 1,2-bis(diphenylphosphino) ethane platinum(II) and palladium(II) complexes. J Inorg Biochem. 1990 Jun; 39(2):117-23. PMID: 2380705.
      View in: PubMed
    96. Newman RA, Siddik ZH, Travis EL, Followill D, Ayele W, Burditt T, Krakoff IH. Assessment of pulmonary and hematologic toxicities of liblomycin, a novel bleomycin analog. Invest New Drugs. 1990 Feb; 8(1):33-41. PMID: 1693138.
      View in: PubMed
    97. Ho BT, Tansey LW, Engineer MS, Newman RA, Siddik ZH, Field WS, Krakoff IH. Beta-adrenoceptor binding studies with LY195448 and metabolites. Res Commun Chem Pathol Pharmacol. 1990 Jan; 67(1):143-6. PMID: 2158135.
      View in: PubMed
    98. Graham RA, Siddik ZH, Hohn DC. Extracorporeal hemofiltration: a model for decreasing systemic drug exposure with intra-arterial chemotherapy. Cancer Chemother Pharmacol. 1990; 26(3):210-4. PMID: 2357769.
      View in: PubMed
    99. Baba H, Siddik ZH, Strebel FR, Jenkins GN, Bull JM. Increased therapeutic gain of combined cis-diamminedichloroplatinum (II) and whole body hyperthermia therapy by optimal heat/drug scheduling. Cancer Res. 1989 Dec 15; 49(24 Pt 1):7041-4. PMID: 2582445.
      View in: PubMed
    100. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989 Nov; 7(11):1748-56. PMID: 2681557.
      View in: PubMed
    101. Siddik ZH, Edwards MJ, Boddie AW. Isolated limb perfusion with chemotherapeutic agents for melanoma: a reevaluation of drug dosimetry. Eur J Cancer Clin Oncol. 1989 Oct; 25(10):1393-7. PMID: 2687001.
      View in: PubMed
    102. Wondergem J, Bulger RE, Siddik ZH, Leygraaf JW, Strebel FR, Alonso M, Travis EL, Bull JM. A comparison of thermal enhancement of cis-diamminedichloroplatinum (II) induced renal and intestinal toxicities by whole body hyperthermia in the rat. Int J Radiat Oncol Biol Phys. 1989 Jun; 16(6):1551-6. PMID: 2722594.
      View in: PubMed
    103. Newman RA, Osborn S, Siddik ZH. Determination of tellurium in biological fluids by means of electrothermal vaporization-inductively coupled plasma-mass spectrometry (ETV-ICP-MS). Clin Chim Acta. 1989 Feb 15; 179(2):191-6. PMID: 2920448.
      View in: PubMed
    104. Siddik ZH, Newman RA. Metabolism of new anticancer agents. Pharmacol Ther. 1989; 41(1-2):163-94. PMID: 2652150.
      View in: PubMed
    105. Wondergem J, Strebel FR, Siddik ZH, Newman RA, Bull JM. The effects of anaesthetics on cisplatinum-induced toxicity at normal temperatures and during whole-body hyperthermia: the influence of NaCl concentration of the vehicle. Int J Hyperthermia. 1988 Nov-Dec; 4(6):643-54. PMID: 3171259.
      View in: PubMed
    106. Siddik ZH, Newman RA. Use of platinum as a modifier in the sensitive detection of tellurium in biological samples. Anal Biochem. 1988 Jul; 172(1):190-6. PMID: 3189763.
      View in: PubMed
    107. Bull JM, Strebel FR, Sunderland BA, Bulger RE, Edwards M, Siddik ZH, Newman RA. o-(beta-Hydroxyethyl)-rutoside-mediated protection of renal injury associated with cis-diamminedichloroplatinum(II)/hyperthermia treatment. Cancer Res. 1988 Apr 15; 48(8):2239-44. PMID: 3349489.
      View in: PubMed
    108. Lautersztain J, Perez-Soler R, Turpin J, Khokhar AR, Siddik ZH, Schmidt K, Lopez-Berestein G. Cellular pharmacology of liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum (II) in mouse resident peritoneal macrophages, Kupffer cells, and hepatocytes. Cancer Res. 1988 Mar 01; 48(5):1300-6. PMID: 3342409.
      View in: PubMed
    109. Siddik ZH, Jones M, Boxall FE, Harrap KR. Comparative distribution and excretion of carboplatin and cisplatin in mice. Cancer Chemother Pharmacol. 1988; 21(1):19-24. PMID: 3277732.
      View in: PubMed
    110. Khokhar AR, Wright K, Siddik ZH, Perez-Soler R. Organ distribution and tumor uptake of liposome entrapped cis-bis-neodecanoato trans-R, R-1,2 diaminocyclohexane platinum (II) administered intravenously and into the proper hepatic artery. Cancer Chemother Pharmacol. 1988; 22(3):223-7. PMID: 3409456.
      View in: PubMed
    111. Dible SE, Siddik ZH, Harrap KR. The comparative tissues distribution of platinum and 14C in mice receiving 14C-labelled carboplatin. Cancer Chemother Pharmacol. 1988; 22(1):11-6. PMID: 3293838.
      View in: PubMed
    112. Newell DR, Siddik ZH, Gumbrell LA, Boxall FE, Gore ME, Smith IE, Calvert AH. Plasma free platinum pharmacokinetics in patients treated with high dose carboplatin. Eur J Cancer Clin Oncol. 1987 Sep; 23(9):1399-405. PMID: 3315699.
      View in: PubMed
    113. Siddik ZH, Newell DR, Boxall FE, Harrap KR. The comparative pharmacokinetics of carboplatin and cisplatin in mice and rats. Biochem Pharmacol. 1987 Jun 15; 36(12):1925-32. PMID: 3297068.
      View in: PubMed
    114. Dible SE, Siddik ZH, Boxall FE, Harrap KR. The effect of diethyldithiocarbamate on the haematological toxicity and antitumour activity of carboplatin. Eur J Cancer Clin Oncol. 1987 Jun; 23(6):813-8. PMID: 2820745.
      View in: PubMed
    115. Siddik ZH, Boxall FE, Harrap KR. Flameless atomic absorption spectrophotometric determination of platinum in tissues solubilized in hyamine hydroxide. Anal Biochem. 1987 May 15; 163(1):21-6. PMID: 3039867.
      View in: PubMed
    116. Siddik ZH, Boxall FE, Harrap KR. Haematological toxicity of carboplatin in rats. Br J Cancer. 1987 Apr; 55(4):375-9. PMID: 3555590.
      View in: PubMed
    117. Gore ME, Hills CA, Siddik ZH, Sloane JP, Winkley AR, Smith IE, Millar JL. Priming reduces the bone marrow toxicity of carboplatin. Eur J Cancer Clin Oncol. 1987 Jan; 23(1):75-80. PMID: 3297714.
      View in: PubMed
    118. Siddik ZH. Minimising the organ toxic effects of chemotherapy. Eur J Cancer Clin Oncol. 1986 Aug; 22(8):905-7. PMID: 3770047.
      View in: PubMed
    119. Calvert AH, Alison DL, Harland SJ, Robinson BA, Jackman AL, Jones TR, Newell DR, Siddik ZH, Wiltshaw E, McElwain TJ, et al. A phase I evaluation of the quinazoline antifolate thymidylate synthase inhibitor, N10-propargyl-5,8-dideazafolic acid, CB3717. J Clin Oncol. 1986 Aug; 4(8):1245-52. PMID: 3734849.
      View in: PubMed
    120. Calvert AH, Harland SJ, Newell DR, Siddik ZH, Harrap KR. Phase I studies with carboplatin at the Royal Marsden Hospital. Cancer Treat Rev. 1985 Sep; 12 Suppl A:51-7. PMID: 3910222.
      View in: PubMed
    121. Millar BC, Siddik ZH, Millar JL, Jinks S. Mesna does not reduce cisplatin induced nephrotoxicity in the rat. Cancer Chemother Pharmacol. 1985; 15(3):307-9. PMID: 3931929.
      View in: PubMed
    122. Harland SJ, Newell DR, Siddik ZH, Chadwick R, Calvert AH, Harrap KR. Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function. Cancer Res. 1984 Apr; 44(4):1693-7. PMID: 6367971.
      View in: PubMed
    123. Trush MA, Mimnaugh EG, Siddik ZH, Gram TE. Bleomycin-metal interaction: ferrous iron-initiated chemiluminescence. Biochem Biophys Res Commun. 1983 Apr 29; 112(2):378-83. PMID: 6189484.
      View in: PubMed
    124. Litterst CL, Tong S, Hirokata Y, Siddik ZH. Stimulation of microsomal drug oxidation in liver and kidney of rats treated with the oncolytic agent cis-dichlorodiammineplatinum-II. Pharmacology. 1983; 26(1):46-53. PMID: 6681909.
      View in: PubMed
    125. Hirokata Y, Tong S, Siddik ZH, Trush MA, Mimnaugh EG, Gram TE. Sex-dependent differences in the effects of portacaval anastomosis on hepatic monooxygenases in rats. Biochem Pharmacol. 1982 Feb 15; 31(4):499-502. PMID: 6802138.
      View in: PubMed
    126. Calvert AH, Harland SJ, Newell DR, Siddik ZH, Jones AC, McElwain TJ, Raju S, Wiltshaw E, Smith IE, Baker JM, Peckham MJ, Harrap KR. Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol. 1982; 9(3):140-7. PMID: 6761010.
      View in: PubMed
    127. Litterst CL, Tong S, Hirokata Y, Siddik ZH. Alterations in hepatic and renal levels of glutathione and activities of glutathione S-transferase from rats treated with cis-dichlorodiammineplatinum-II. Cancer Chemother Pharmacol. 1982; 8(1):67-71. PMID: 7201357.
      View in: PubMed
    128. Drew R, Siddik ZS. Drug uptake by lung slices from paraquat-pretreated rats. Experientia. 1981 Oct 15; 37(10):1093-5. PMID: 7308402.
      View in: PubMed
    129. Drew R, Siddik ZH, Mimnaugh EG, Gram TE. Species and dose differences in the accumulation of imipramine by mammalian lungs. Drug Metab Dispos. 1981 Jul-Aug; 9(4):322-6. PMID: 6114830.
      View in: PubMed
    130. Siddik ZH, Drew R, Gram TE. Metabolism and biliary excretion of sulfobromophthalein in vitamin A deficiency. Biochem Pharmacol. 1980 Oct 01; 29(19):2583-8. PMID: 7426064.
      View in: PubMed
    131. Siddik ZH, Mimnaugh EG, Trush MA, Gram TE. The effect of vitamin A deficiency on hepatic, renal and pulmonary glutathione S-transferase activities in the rat. Biochem J. 1980 Jun 15; 188(3):889-93. PMID: 7470042.
      View in: PubMed
    132. Sikic BI, Siddik ZH, Gram TE. Relative pulmonary toxicity and antitumor effects of two new bleomycin analogs, pepleomycin and tallysomycin A. Cancer Treat Rep. 1980 Apr-May; 64(4-5):659-67. PMID: 6159079.
      View in: PubMed
    133. Siddik ZH, Drew R, Litterst CL, Mimnaugh EG, Sikic BI, Gram TE. Hepatic cytochrome P-450-dependent metabolism and enzymatic conjugation of foreign compounds in vitamin A-deficient rats. Pharmacology. 1980; 21(6):383-90. PMID: 7220590.
      View in: PubMed
    134. Siddik ZH, Trush MA, Gram TE. Pulmonary accumulation of drugs in vitamin A deficiency. Lung. 1980; 157(4):209-17. PMID: 7401686.
      View in: PubMed
    135. Drew R, Siddik ZH. Effect of a specific 5HT uptake inhibitor (citalopram) on drug accumulation by rat lung slices. Pharmacology. 1980; 20(1):27-31. PMID: 6929555.
      View in: PubMed
    136. Siddik ZH, Barnes RD, Dring LG, Smith RL, Williams RT. The fate of lysergic acid DI[14C]ethylamide ([14C]LSD) in the rat, guinea pig and rhesus monkey and of [14C]iso-LSD in rat. Biochem Pharmacol. 1979 Oct 15; 28(20):3093-101. PMID: 117811.
      View in: PubMed
    137. Siddik ZH, Barnes RD, Dring LG, Smith RL, Williams RT. The metabolism of lysergic acid DI[14C]ethylamide ([14C]LSD) in the isolated perfused rat liver. Biochem Pharmacol. 1979 Oct 15; 28(20):3081-91. PMID: 518707.
      View in: PubMed
    138. Siddik ZH, Drew R, Gram TE. The effect of chlorpromazine on the uptake and efflux of paraquat in rat lung slices. Toxicol Appl Pharmacol. 1979 Sep 30; 50(3):443-50. PMID: 516057.
      View in: PubMed
    139. Drew R, Siddik ZH, Gram TE. Uptake and efflux of 14C-paraquat by rat lung slices: the effect of imipramine and other drugs. Toxicol Appl Pharmacol. 1979 Jul; 49(3):473-8. PMID: 473214.
      View in: PubMed
    140. Mimnaugh EG, Siddik ZH, Trush MA, Drew R, Gram TE. The effect of unilateral pneumonectomy on in vitro drug metabolism by the contralateral lung of rabbits. Drug Metab Dispos. 1979 Jul-Aug; 7(4):208-10. PMID: 39721.
      View in: PubMed
    141. Mimnaugh EG, Siddik ZH, Drew R, Sikic BI, Gram TE. The effects of alpha-tocopherol on the toxicity, disposition, and metabolism of adriamycin in mice. Toxicol Appl Pharmacol. 1979 Jun 15; 49(1):119-26. PMID: 473197.
      View in: PubMed
    142. Siddik ZH, Sikic BI, Drew R, Mimnaugh EG, Litterst CL, Gram TE. Lack of correlation between cortisol-induced precocious maturation of the fetal rabbit lung and drug metabolism. Biochem Pharmacol. 1979 Mar 01; 28(5):683-5. PMID: 444254.
      View in: PubMed
    143. Siddik ZH, Barnes RD, Dring LG, Smith RL, Williams RT. The fate of lysergic acid di[ 14C]ethlamide ([14-C-A1LSD) in the rat. Biochem Soc Trans. 1975; 3(2):290-2. PMID: 1132562.
      View in: PubMed
    144. Synthesis and antitumor activity of new trans-1R,2R-diaminocyclohexaneplatinum(II) complexes containing disubstituted sulfide groups. Inorganica Chimica Acta. 241:101-104.
    145. Drug resistance in cancer cells.
    146. Synthesis and characterization of new antitumor TRANS-R, R-, TRANS-S, S- AND CIS- 1, 2-diaminocyclohexane platinum (IV) complexes. Journal of Coordination Chemistry. 31:109-116.
    147. Drug resistance and the tumor suppressor p53. 209-231.
    148. Hyperthermic potentiation of carboplatin-induced cytotoxicity. Surgical Forum. 39:433-435.
    149. Activation of Platinum(IV) Prodrugs By Motexafin Gadolinium as a Redox Mediator. Angewandte Chemie - International Edition. 55:12626-12631.
    150. A texaphyrin-oxaliplatin conjugate that overcomes both pharmacologic and molecular mechanisms of cisplatin resistance in cancer cells. MedChemComm. 3:1275-1281.
    151. Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum II (CBDCA, JM8) in mice and rats. 659.
    152. Direct intratumoral injection of a novel collagen matrix gel and cisplatin effectively controls experimental liver tumors. Cancer Research Therapy and Control. 4:247-254.
    153. Pharmacokinetic and toxicity studies with CB 3717. British Journal of Cancer. 46:467-468.
    154. Erratum. Journal of Clinical Investigation. 123:5411.
    155. Phase i study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy. Clinical Epigenetics. 7:1-11.
    156. Use of a solubilisation procedure in the determination of platinum (Pt) in rodent and human tissues following carboplatin (JM8, CBDCA) administration.
    157. The effect of basic drugs on the uptake and efflux of paraquat in rat lung. Pharmacologist. 20:273.
    158. Relative pulmonary toxicity and antitumor effects of two new bleomycin analogues, pepleomycin and tallisomycin A.
    159. Pharmacokinetic and toxicity studies with CB 3717.
    160. New bipyridine gold(III) dithiocarbamate-containing complexes exerted a potent anticancer activity against cisplatin-resistant cancer cells independent of p53 status. Oncotarget. 8:490-505.
    161. In situ localization and quantitation of anticancer drugs. Cancer Bulletin. 46:67-71.
    162. Pulmonary accumulation of imipramine. Clinical and Experimental Pharmacology and Physiology. 6:658-659.
    163. Frontispiece. Angewandte Chemie - International Edition. 55.
    164. Apoptosis in Cancer. Mechanisms, Deregulation, and Therapeutic Targeting. 357-390.
    165. Corrigendum. Chemistry - A European Journal. 21:3520.
    166. Heterozygous p53V172F mutation in cisplatin-resistant human tumor cells promotes MDM4 recruitment and decreases stability and transactivity of p53. Oncogene.
    167. Photoinduced reduction of PtIV within an anti-proliferative PtIV-texaphyrin conjugate. Chemistry - A European Journal. 20:8942-8947.
    168. Modulation of the haematological, renal and gastrointestinal toxicities of cisplatin and carboplatin when administered via the oral route in rodents. Pharmacology Communications. 3:9-18.
    SIDDIK's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description